Abbott To Bolster Biaxin XL Patent Protection Ahead Of Compound Expiration In May
This article was originally published in The Pink Sheet Daily
Executive Summary
The additional intellectual property for the extended-release formulation will give generic firms “something to think about,” Abbott CFO Freyman says at SG Cowen investor conference. Abbott says it filed suit against three generic manufacturers March 14.